Mycophenolate mofetil
Drugs technology
1750 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Mycophenolate Mofetil-TL has an immunosuppressive effect. Selectively inhibits inosine monophosphate dehydrogenase and inhibits the synthesis of guanosine nucleotide. It has a pronounced cytostatic effect on lymphocytes, inhibits their proliferation, and inhibits the formation of antibodies by B-lymphocytes. When taken orally, it is rapidly absorbed and fully hydrolyzed, forming mycophenolic acid. Excreted mainly by the kidneys. In combination with azathioprine and cyclosporine, as well as with the induction course of antithymocyte globulin, reduces the incidence of adverse outcomes in the first 6 months after transplantation.
Indications
Prevention of the reaction of rejection and treatment of rejection of allogenic renal graft (in combination with cyclosporin A and glucocorticoids).
Composition
1 capsule contains:
Active substances: mycophenolate mofetil 500 mg.
Mycophenolate mofetil is marketed under different brands and generic names, and comes in different dosage forms:
| Brand name | Manufacturer | Country | Dosage form |
|---|---|---|---|
| Mycophenolate Mofetil-TL | Drugs technology | Russia | pills |
| Mycophenolate-Teva | Teva | Israel | capsules |
No customer reviews for the moment.
Dosage and Administration
Applied as part of combination therapy with cyclosporine and corticosteroids. To prevent graft rejection, the first dose of mycophenolate mofetil is taken within the first 3 days after surgery. When taken orally, the recommended dose is 2 g per day, the frequency of reception - 2 times a day. For the treatment of rejection reactions - 3 g per day.
Adverse reactions
Nausea, vomiting, diarrhea, constipation, leukopenia or leukocytosis, anemia, thrombocytopenia, an increase in the frequency of infectious and septic complications; headaches, insomnia, tremor, fever, asthenia, lumbago, hypertension, cough, pharyngitis, dyspnea, peripheral edema, oropharyngeal candidiasis, hematuria, canalicular necrosis, impotence, acne, hyper- or hypocalymia, hyperglycemia, hypophosphate, hyperplasia, hypophosphate rash, pruritus.
Contraindications
Hypersensitivity, exacerbation of gastric ulcer and duodenal ulcer and other diseases of the gastrointestinal tract, pregnancy, breast-feeding, child age.
Drug interactions
Probenecid and other drugs that affect tubular secretion, increase the plasma concentration of mycophenolic acid. Antacids containing hydroxides of magnesium and aluminum, reduce absorption. Drugs that alter the flora of the gastrointestinal tract, can disrupt the enterohepatic circulation. Reduces the effectiveness of oral contraception. Azathioprine increases the risk of developing lymphomas, especially skin.
Special instructions
It is necessary to take into account the possibility of increasing the risk of lymphoproliferative processes, regularly monitor the composition of peripheral blood, while reducing the number of neutrophils shows dose reduction or a break in treatment (and appropriate therapy). In the case of reducing the glomerular filtration rate below, it is not recommended to use more than 2 times a day. For more information, see the instructions for medical use of the drug.
Overdosage
Symptoms: an increase in the frequency of gastrointestinal and hematological (in particular neutropenia) side effects.
Treatment: dose reduction or drug withdrawal. To accelerate the excretion of possible sequestrants bile acids. Small amounts of glucuronide can be removed by hemodialysis (mycophenolic acid is not dialyzed).
- Brand name: Mycophenolate Mofetil-TL
- Active ingredient: Mycophenolate mofetil
- Dosage form: Pills
- Manufacturer: Drug technology
- Country of Origin: Russia
Studies and clinical trials of Mycophenolate mofetil (Click to expand)
- Foetal rat pancreatic transplantation: posttransplantation development of foetal pancreatic iso- and allografts and suppression of rejection with mycophenolate mofetil (MMF) and cyclosporine based immunesuppression
- Treatment of myasthenia gravis with mycophenolate mofetil: A case report
- Mycophenolate mofetil for interstitial lung disease in dermatomyositis
- Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis
- Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
- Acquired and reversible Pelger-Huët anomaly of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil therapy
- T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: Response to cyclosporin A and mycophenolate mofetil
- Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura
- Acquired pure megakaryocytic aplasia: Report of a single case treated with mycophenolate mofetil
- Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis
- In utero exposure to mycophenolate mofetil: A characteristic phenotype?
- Mycophenolate mofetil embryopathy may be dose and timing dependent
- Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: Phenocopy for Fryns syndrome or broad spectrum of teratogenic effects?
- Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature
- Intrauterine exposure to mycophenolate mofetil and multiple congenital anomalies in a newborn: Possible teratogenic effect
- An additional patient with mycophenolate mofetil embryopathy: Cardiac and facial analyses
- Treatment of systemic lupus erythematosus–associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil
- Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis
- Acute inflammatory syndrome following introduction of mycophenolate mofetil in a patient with systemic lupus erythematosus
- Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial
- Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil
- Individual dosing regimen of mycophenolate mofetil in lupus patients: Comment on the article by Zahr et al
- Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats
- Insulin-like growth factor I improves aspects of mycophenolate mofetil-impaired anastomotic healing in an experimental model
7 other products in the same category:
arrow_upward